SG10201913245UA - Antibody/t-cell receptor chimeric constructs and uses thereof - Google Patents
Antibody/t-cell receptor chimeric constructs and uses thereofInfo
- Publication number
- SG10201913245UA SG10201913245UA SG10201913245UA SG10201913245UA SG10201913245UA SG 10201913245U A SG10201913245U A SG 10201913245UA SG 10201913245U A SG10201913245U A SG 10201913245UA SG 10201913245U A SG10201913245U A SG 10201913245UA SG 10201913245U A SG10201913245U A SG 10201913245UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- cell receptor
- chimeric constructs
- receptor chimeric
- constructs
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245944P | 2015-10-23 | 2015-10-23 | |
US201662304918P | 2016-03-07 | 2016-03-07 | |
US201662345649P | 2016-06-03 | 2016-06-03 | |
US201662369694P | 2016-08-01 | 2016-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913245UA true SG10201913245UA (en) | 2020-02-27 |
Family
ID=58558140
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913247XA SG10201913247XA (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
SG10201913245UA SG10201913245UA (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
SG11201802895QA SG11201802895QA (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913247XA SG10201913247XA (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802895QA SG11201802895QA (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (6) | US11421013B2 (en) |
EP (2) | EP3365364B1 (en) |
JP (2) | JP7316042B2 (en) |
KR (1) | KR20180063325A (en) |
CN (4) | CN107614519B (en) |
AU (2) | AU2016342041B2 (en) |
CA (1) | CA3001137A1 (en) |
HK (2) | HK1248243A1 (en) |
IL (2) | IL258405B (en) |
MX (1) | MX2018004721A (en) |
MY (1) | MY194628A (en) |
PH (1) | PH12018500861A1 (en) |
RU (2) | RU2022103665A (en) |
SG (3) | SG10201913247XA (en) |
TW (2) | TW202321288A (en) |
WO (1) | WO2017070608A1 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913937QA (en) * | 2014-12-05 | 2020-03-30 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
PL3227339T3 (en) | 2014-12-05 | 2022-02-21 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
SG10201913247XA (en) * | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3039406A1 (en) | 2016-09-19 | 2018-03-22 | University Of Southern California | Non-radioactive cytotoxicity assays |
WO2018102795A2 (en) * | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
KR20200014294A (en) | 2017-04-26 | 2020-02-10 | 유레카 쎄라퓨틱스, 인코포레이티드 | Chimeric Antibody / T-Cell Receptor Constructs and Uses thereof |
SG11201909728XA (en) | 2017-04-26 | 2019-11-28 | Eureka Therapeutics Inc | Constructs specifically recognizing glypican 3 and uses thereof |
CR20200014A (en) * | 2017-07-14 | 2020-06-11 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
CN111315769A (en) * | 2017-09-06 | 2020-06-19 | 加州理工学院 | Dual-function receptor for signaling and antigen presentation (SABR) |
MA50185A (en) | 2017-09-22 | 2020-07-29 | Wuxi Biologics Ireland Ltd | NEW BISPECIFIC CD3 / CD19 POLYPEPTID COMPLEXES |
AU2018334886A1 (en) | 2017-09-22 | 2020-04-09 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
MX2020004185A (en) * | 2017-09-27 | 2021-01-08 | Univ Southern California | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy. |
GB201718088D0 (en) * | 2017-11-01 | 2017-12-13 | Autolus Ltd | Vectors |
CN109971715A (en) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | A kind of cultural method of specific amplification CAR-T cell |
JPWO2019151392A1 (en) * | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | Antigen-specific MHC expression regulation method |
GB201801920D0 (en) * | 2018-02-06 | 2018-03-21 | Autolus Ltd | Polypeptides and methods |
WO2019161133A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
JP7404331B2 (en) * | 2018-03-23 | 2023-12-25 | ガビッシュ-ガリラヤ バイオ アプリケーションズ リミテッド | Nucleic acid molecules encoding membrane-bound IL-10 and genetically reprogrammed Tregs expressing the same |
MX2020010227A (en) * | 2018-03-30 | 2021-02-17 | Eureka Therapeutics Inc | Constructs targeting cd22 and uses thereof. |
CN110407927B (en) * | 2018-04-26 | 2022-09-09 | 香雪生命科学技术(广东)有限公司 | TCR (T cell receptor) capable of recognizing AFP (alpha fetoprotein) antigen |
JP2021525509A (en) * | 2018-06-01 | 2021-09-27 | ユニバーシティ オブ サザン カリフォルニア | Diverse antigen-binding domains for cell therapy, new platforms and other enhancements |
JP2021526844A (en) * | 2018-06-18 | 2021-10-11 | ユーリカ セラピューティックス, インコーポレイテッド | Constructs that target prostate-specific membrane antigens (PSMA) and their use |
CN110818802B (en) * | 2018-08-08 | 2022-02-08 | 华夏英泰(北京)生物技术有限公司 | Chimeric T cell receptor STAR and application thereof |
MX2021005751A (en) | 2018-11-16 | 2021-10-01 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof. |
US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
WO2020150364A1 (en) * | 2019-01-15 | 2020-07-23 | Altor Bioscience, Llc | Human immunodeficiency virus-specific t cell receptors |
CN110006724B (en) * | 2019-04-17 | 2021-06-04 | 郑州安图生物工程股份有限公司 | Reagent for detecting trichomonas by adopting papanicolaou and gram staining method |
DE102019121007A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins that specifically bind to MAGE-A |
WO2021026266A1 (en) * | 2019-08-05 | 2021-02-11 | Distributed Bio, Inc. | Antigen binding molecules and methods of screening thereof |
WO2021030153A2 (en) * | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
MX2022002723A (en) * | 2019-09-05 | 2022-03-22 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) that bind bcma. |
EP4028033A4 (en) * | 2019-09-12 | 2023-10-04 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
KR20220131253A (en) * | 2019-12-30 | 2022-09-27 | 차이나 이뮤노테크 (베이징) 바이오테크놀로지 컴퍼니 리미티드 | Improved T-cell receptor STAR and its application |
EP4087620A1 (en) * | 2020-01-10 | 2022-11-16 | TCR2 Therapeutics Inc. | Compositions and methods for autoimmunity regulation |
CN111320703A (en) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | Chimeric antigen receptor targeting CD22 and application thereof |
CN115605503A (en) | 2020-03-20 | 2023-01-13 | 莱尔免疫制药股份有限公司(Us) | Novel recombinant cell surface markers |
IL297751A (en) | 2020-04-28 | 2022-12-01 | Lyell Immunopharma Inc | Methods for culturing cells |
WO2021238903A1 (en) * | 2020-05-25 | 2021-12-02 | 华夏英泰(北京)生物技术有限公司 | Enhanced synthetic t-cell receptor and antigen receptor |
CN116997563A (en) | 2021-01-27 | 2023-11-03 | 莱尔免疫制药股份有限公司 | Improved immune cell therapy |
KR20230150833A (en) | 2021-02-25 | 2023-10-31 | 라이엘 이뮤노파마, 인크. | Cell culture method |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
CA3226276A1 (en) * | 2021-07-29 | 2023-02-02 | Nantcell, Inc. | Modified t cell receptors for the prevention and treatment of viral infections and cancer |
WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
WO2023070041A1 (en) | 2021-10-21 | 2023-04-27 | Lyell Immunopharma, Inc. | Enhanced immune cell therapy |
CA3234822A1 (en) | 2021-10-28 | 2023-05-04 | Suman Kumar VODNALA | Methods for culturing cells expressing ror1-binding protein |
WO2023077032A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
WO2023076511A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
WO2023133540A1 (en) | 2022-01-07 | 2023-07-13 | Lyell Immunopharma, Inc. | Il-12 affinity variants |
WO2024020429A1 (en) | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
WO1997002342A1 (en) | 1995-06-30 | 1997-01-23 | Københavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-mhc complex |
DE19544393A1 (en) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistic herbicidal mixtures |
AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
MXPA02008265A (en) | 2000-02-24 | 2004-09-10 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells. |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
LT2857516T (en) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (en) * | 2002-02-20 | 2006-04-26 | Dyax Corp | Mhc-peptide complex binding ligands |
CN102093477B (en) | 2002-05-22 | 2014-02-26 | 艾斯巴技术-诺华有限责任公司 | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
EP1629011B1 (en) | 2003-05-31 | 2010-01-13 | Micromet AG | Human anti-human cd3 binding molecules |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
ES2592271T3 (en) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide production methods by regulating the association of polypeptides |
ZA200710496B (en) * | 2005-06-02 | 2009-04-29 | Astrazeneca Ab | Antibodies directed to CD20 and used thereof |
AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CN101316610A (en) | 2005-09-22 | 2008-12-03 | 艾润·R·科恩 | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom |
US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
BRPI0710971A2 (en) | 2006-04-28 | 2011-05-31 | Esbatech Ag | antibodies that bind to the extracellular domain of the tyrosine kinase alk receptor, their use, expression vector, method of production of an antibody, vaccine and alkaline epitope |
DK2016102T3 (en) | 2006-05-03 | 2012-07-02 | Us Gov Health & Human Serv | Chimeric T cell receptors and associated materials and methods of use |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
WO2007143104A2 (en) | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
DK2066349T3 (en) | 2006-09-08 | 2012-07-09 | Medimmune Llc | HUMANIZED ANTI-CD19 ANTIBODIES AND USE THEREOF IN TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES |
US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
MX351227B (en) | 2008-06-25 | 2017-09-14 | Athenix Corp | Toxin genes and methods for their use. |
PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
US20100153133A1 (en) | 2008-12-16 | 2010-06-17 | International Business Machines Corporation | Generating Never-Event Cohorts from Patient Care Data |
US20110311517A1 (en) | 2009-02-10 | 2011-12-22 | Shenogen Pharma Group, Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
US20120251579A1 (en) | 2009-07-30 | 2012-10-04 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Compositions for generating an antigen specific immune response |
CN102666576A (en) | 2009-10-22 | 2012-09-12 | 里卡多·J·莫罗 | Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
JP6082997B2 (en) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | T cell receptor-like antibody to WT1 peptide presented by HLA-A2 |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
EP2843051B1 (en) | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
CN103319595B (en) | 2012-07-04 | 2016-12-28 | 中国药科大学 | Anti-human AFP single-chain antibody and the preparation method and application of fused antigen peptide |
AU2013289971A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
US20150183877A1 (en) * | 2012-07-18 | 2015-07-02 | Eli Lilly And Company | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains |
ES2714523T3 (en) | 2012-09-04 | 2019-05-28 | Cellectis | Chimeric receptor of multi-chain antigens and uses thereof |
ES2743738T3 (en) | 2012-10-02 | 2020-02-20 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
CN102993305B (en) | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof |
AU2013359001A1 (en) | 2012-12-13 | 2015-07-23 | The Board Of Regents Of The University Of Oklahoma | Target peptides for ovarian cancer therapy and diagnostics |
CN103965362B (en) | 2013-02-06 | 2019-02-01 | 上海细胞治疗集团有限公司 | A kind of chimeric chemokine receptor for making T cell tend to tumor locus |
JPWO2014123165A1 (en) | 2013-02-06 | 2017-02-02 | 旭硝子株式会社 | Transparent surface material and display device using the same |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
CN105208866B (en) | 2013-03-21 | 2018-11-23 | 桑格摩生物治疗股份有限公司 | Use engineering zinc finger protein nuclease targeted disruption T cell receptor gene |
KR101536668B1 (en) | 2013-06-18 | 2015-07-15 | 사회복지법인 삼성생명공익재단 | Antibodies cross-reactive to Human and Mouse c-Met and Uses thereof |
GB201313377D0 (en) | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
WO2015063069A1 (en) | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
CN104087592B (en) | 2014-05-13 | 2016-01-27 | 天津医科大学总医院 | AFP 158-166specificity TCR gene and transgenic T cells thereof and in-vitro multiplication method and purposes |
CN114456272A (en) | 2015-04-03 | 2022-05-10 | 优瑞科生物技术公司 | Constructs targeting AFP peptide/MHC complexes and uses thereof |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
KR20180083859A (en) | 2015-10-13 | 2018-07-23 | 유레카 쎄라퓨틱스, 인코포레이티드 | Antibody Agents Specific for Human CD19 and Uses Thereof |
SG10201913247XA (en) | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
CN105331585A (en) | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent |
-
2016
- 2016-10-21 SG SG10201913247XA patent/SG10201913247XA/en unknown
- 2016-10-21 MX MX2018004721A patent/MX2018004721A/en unknown
- 2016-10-21 WO PCT/US2016/058305 patent/WO2017070608A1/en active Application Filing
- 2016-10-21 JP JP2018520406A patent/JP7316042B2/en active Active
- 2016-10-21 KR KR1020187014004A patent/KR20180063325A/en not_active Application Discontinuation
- 2016-10-21 RU RU2022103665A patent/RU2022103665A/en unknown
- 2016-10-21 EP EP16858388.8A patent/EP3365364B1/en active Active
- 2016-10-21 SG SG10201913245UA patent/SG10201913245UA/en unknown
- 2016-10-21 AU AU2016342041A patent/AU2016342041B2/en active Active
- 2016-10-21 IL IL258405A patent/IL258405B/en unknown
- 2016-10-21 RU RU2018118652A patent/RU2767209C2/en active
- 2016-10-21 US US15/769,724 patent/US11421013B2/en active Active
- 2016-10-21 CA CA3001137A patent/CA3001137A1/en active Pending
- 2016-10-21 EP EP20214936.5A patent/EP3842450A1/en active Pending
- 2016-10-21 MY MYPI2018000550A patent/MY194628A/en unknown
- 2016-10-21 CN CN201680023511.2A patent/CN107614519B/en active Active
- 2016-10-21 CN CN202210862478.XA patent/CN115927191A/en active Pending
- 2016-10-21 SG SG11201802895QA patent/SG11201802895QA/en unknown
- 2016-10-21 CN CN202210865517.1A patent/CN116059316A/en active Pending
- 2016-10-21 CN CN202210861652.9A patent/CN115925973A/en active Pending
- 2016-10-21 IL IL295398A patent/IL295398A/en unknown
- 2016-10-24 TW TW111134706A patent/TW202321288A/en unknown
- 2016-10-24 TW TW105134336A patent/TWI780031B/en active
-
2017
- 2017-12-01 US US15/829,793 patent/US10098951B2/en active Active
-
2018
- 2018-04-20 PH PH12018500861A patent/PH12018500861A1/en unknown
- 2018-06-11 HK HK18107532.0A patent/HK1248243A1/en unknown
- 2018-09-04 US US16/121,475 patent/US10464988B2/en active Active
-
2019
- 2019-01-15 HK HK19100638.7A patent/HK1258274A1/en unknown
- 2019-10-29 US US16/667,781 patent/US10822389B2/en active Active
-
2021
- 2021-02-22 US US17/181,913 patent/US20210253665A1/en active Pending
- 2021-12-17 JP JP2021204862A patent/JP2022050431A/en active Pending
-
2022
- 2022-02-25 AU AU2022201334A patent/AU2022201334A1/en active Pending
- 2022-04-08 US US17/716,667 patent/US20220348629A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258274A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
SG10201913579WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
IL274921A (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
EP3564266A4 (en) | Novel chimeric antigen receptor and use thereof | |
IL254254A0 (en) | Chimeric antigen receptor | |
AU2015269219B2 (en) | Mesothelin-targeted chimeric antigen receptors and uses thereof | |
EP3256492A4 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
EP3259352A4 (en) | Chimeric antigen receptors and uses thereof | |
GB201503742D0 (en) | Chimeric antigen receptor | |
SG11201606790XA (en) | Chimeric antigen receptor | |
FI3169703T4 (en) | Chimeric antigen receptor and its use | |
GB201607968D0 (en) | Chimeric antigen receptor | |
EP3347474A4 (en) | Chimeric antigen receptors and uses thereof | |
GB201610512D0 (en) | Chimeric antigen receptor | |
ZA201906321B (en) | Chimeric antigen receptor | |
GB201709508D0 (en) | Chimeric antigen receptor | |
GB2585607B (en) | Chimeric antigen receptor and application thereof | |
GB201519900D0 (en) | Chimeric antigen receptor | |
GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
GB201721421D0 (en) | Chimeric antigen receptor | |
AU2015903719A0 (en) | Chimeric antigen receptor and uses thereof | |
GB201612844D0 (en) | Chimeric antigen receptor | |
GB201612533D0 (en) | Chimeric antigen receptor | |
GB201604387D0 (en) | Chimeric antigen receptor | |
AU2014902457A0 (en) | Chimeric antigen receptor and uses thereof |